Soluble vascular endothelial growth factor decoy receptor FP3 exerts potent antiangiogenic effects

Molecular Therapy

Volumn 20, Issue 5, 2012, Pages 938-947

  Yu, De Chao ^a   Lee, Jung Sun ^b   Yoo, Ji Young ^b   Shin, Hyewon ^b   Deng, Hongxin ^a   Wei, Yuquan ^a   Yun, Chae Ok ^c  

^a SICHUAN UNIVERSITY   (China)

^b Yonsei University College of Medicine   (South Korea)

^c Hanyang University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; FLUOROURACIL; FP3; IMMUNOGLOBULIN G; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL DENSITY; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; COLON CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; DRUG POTENTIATION; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL;

RATTUS;

EID: 84862831222     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2011.285     Document Type: Article

References (40)

1. Hanahan, D and Folkman, J (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364. (Pubitemid 26272076)
2. Ferrara, N and Alitalo, K (1999). Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 5: 1359-1364.
3. Holash, J, Davis, S, Papadopoulos, N, Croll, SD, Ho, L, Russell, M et al. (2002). VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99: 11393-11398. (Pubitemid 34920936)
4. Kim, KJ, Li, B, Winer, J, Armanini, M, Gillett, N, Phillips, HS et al. (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844. (Pubitemid 23132159)
5. Yancopoulos, GD, Davis, S, Gale, NW, Rudge, JS, Wiegand, SJ and Holash, J (2000). Vascular-specific growth factors and blood vessel formation. Nature 407: 242-248.
6. Keyt, BA, Nguyen, HV, Berleau, LT, Duarte, CM, Park, J, Chen, H et al. (1996). Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis. J Biol Chem 271: 5638-5646.
7. Shalaby, F, Rossant, J, Yamaguchi, TP, Gertsenstein, M, Wu, XF, Breitman, ML et al. (1995). Failure of blood-island formation and vasculogenesis in Flk-1-deficient mice. Nature 376: 62-66.
8. Fong, GH, Rossant, J, Gertsenstein, M and Breitman, ML (1995). Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium. Nature 376: 66-70.
9. Volm, M, Koomägi, R and Mattern, J (1997). Prognostic value of vascular endothelial growth factor and its receptor Flt-1 in squamous cell lung cancer. Int J Cancer 74: 64-68. (Pubitemid 27157857)
10. Lu, D, Kussie, P, Pytowski, B, Persaud, K, Bohlen, P, Witte, L et al. (2000). Identification of the residues in the extracellular region of KDR important for interaction with vascular endothelial growth factor and neutralizing anti-KDR antibodies. J Biol Chem 275: 14321-14330. (Pubitemid 30339714)
11. Asano, M, Yukita, A, Matsumoto, T, Hanatani, M and Suzuki, H (1998). An anti-human VEGF monoclonal antibody, MV833, that exhibits potent anti-tumor activity in vivo. Hybridoma 17: 185-190. (Pubitemid 28234853)
12. Kamiya, K, Konno, H, Tanaka, T, Baba, M, Matsumoto, K, Sakaguchi, T et al. (1999). Antitumor effect on human gastric cancer and induction of apoptosis by vascular endothelial growth factor neutralizing antibody. Jpn J Cancer Res 90: 794-800. (Pubitemid 29381111)
13. Prewett, M, Huber, J, Li, Y, Santiago, A, O'Connor, W, King, K et al. (1999). Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 59: 5209-5218. (Pubitemid 29503984)
14. Ferrara, N, Chen, H, Davis-Smyth, T, Gerber, HP, Nguyen, TN, Peers, D et al. (1998). Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 4: 336-340. (Pubitemid 28144094)
15. Gerber, HP, Vu, TH, Ryan, AM, Kowalski, J, Werb, Z and Ferrara, N (1999). VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat Med 5: 623-628. (Pubitemid 29289424)
16. Martin, L and Schilder, R (2007). Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition. J Clin Oncol 25: 2894-2901. (Pubitemid 47123153)
17. Kamba, T and McDonald, DM (2007). Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96: 1788-1795. (Pubitemid 46912024)
18. O'Reilly, MS (2002). The combination of antiangiogenic therapy with other modalities. Cancer J 8 Suppl 1: S89-S99.
19. Jain, RK, Duda, DG, Clark, JW and Loeffler, JS (2006). Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 3: 24-40. (Pubitemid 43108832)
20. Shinkai, A, Ito, M, Anazawa, H, Yamaguchi, S, Shitara, K and Shibuya, M (1998). Mapping of the sites involved in ligand association and dissociation at the extracellular domain of the kinase insert domain-containing receptor for vascular endothelial growth factor. J Biol Chem 273: 31283-31288. (Pubitemid 28533144)
21. Fuh, G, Li, B, Crowley, C, Cunningham, B and Wells, JA (1998). Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor. J Biol Chem 273: 11197-11204. (Pubitemid 28204970)
22. Kuhn, H, Hammerschmidt, S and Wirtz, H (2007). Targeting tumorangiogenesis in lung cancer by suppression of VEGF and its receptor-results from clinical trials and novel experimental approaches. Curr Med Chem 14: 3157-3165.
23. Ferrara, N (1995). The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 36: 127-137.
24. Zhu, Z and Witte, L (1999). Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonists to the receptors of vascular endothelial growth factor. Invest New Drugs 17: 195-212. (Pubitemid 30037954)
25. Millauer, B, Shawver, LK, Plate, KH, Risau, W and Ullrich, A (1994). Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 367: 576-579.
26. Skobe, M, Rockwell, P, Goldstein, N, Vosseler, S and Fusenig, NE (1997). Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 3: 1222-1227. (Pubitemid 27508822)
27. Gerber, HP, McMurtrey, A, Kowalski, J, Yan, M, Keyt, BA, Dixit, V et al. (1998). Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 273: 30336-30343. (Pubitemid 28545503)
28. Gupta, K, Kshirsagar, S, Li, W, Gui, L, Ramakrishnan, S, Gupta, P et al. (1999). VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res 247: 495-504. (Pubitemid 29394787)
29. Ross, J (1996). Comments on the article "Persistent confusion of total entropy and chemical system entropy in chemical thermodynamics" [(1996) Proc. Natl. Acad. Sci. USA 93, 7452-7453]. Proc Natl Acad Sci USA 93: 14314; discussion 14315.
30. Holmgren, L, O'Reilly, MS and Folkman, J (1995). Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1: 149-153.
31. Mauceri, HJ, Hanna, NN, Beckett, MA, Gorski, DH, Staba, MJ, Stellato, KA et al. (1998). Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394: 287-291. (Pubitemid 28335042)
32. Teicher, BA, Williams, JI, Takeuchi, H, Ara, G, Herbst, RS and Buxton, D (1998). Potential of the aminosterol, squalamine in combination therapy in the rat 13,762 mammary carcinoma and the murine Lewis lung carcinoma. Anticancer Res 18(4A): 2567-2573. (Pubitemid 28386552)
33. Katoh, O, Tauchi, H, Kawaishi, K, Kimura, A and Satow, Y (1995). Expression of the vascular endothelial growth factor (VEGF) receptor gene, KDR, in hematopoietic cells and inhibitory effect of VEGF on apoptotic cell death caused by ionizing radiation. Cancer Res 55: 5687-5692.
34. Katoh, O, Takahashi, T, Oguri, T, Kuramoto, K, Mihara, K, Kobayashi, M et al. (1998). Vascular endothelial growth factor inhibits apoptotic death in hematopoietic cells after exposure to chemotherapeutic drugs by inducing MCL1 acting as an antiapoptotic factor. Cancer Res 58: 5565-5569. (Pubitemid 28551146)
35. Zhang, M, Zhang, J, Yan, M, Luo, D, Zhu, W, Kaiser, PK et al. (2011). A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative agerelated macular degeneration. Ophthalmology 118: 672-678.
36. Zhang, M, Zhang, J, Yan, M, Li, H, Yang, C and Yu, D (2008). Recombinant antivascular endothelial growth factor fusion protein efficiently suppresses choridal neovasularization in monkeys. Mol Vis 14: 37-49.
37. Yoo, JY, Kim, JH, Kim, J, Huang, JH, Zhang, SN, Kang, YA et al. (2008). Short hairpin RNA-expressing oncolytic adenovirus-mediated inhibition of IL-8: effects on antiangiogenesis and tumor growth inhibition. Gene Ther 15: 635-651. (Pubitemid 351524518)
38. Lee, JS, Song, SH, Kim, JM, Shin, IS, Kim, KL, Suh, YL et al. (2008). Angiopoietin-1 prevents hypertension and target organ damage through its interaction with endothelial Tie2 receptor. Cardiovasc Res 78: 572-580. (Pubitemid 351769771)
39. Kwon, OJ, Kim, PH, Huyn, S, Wu, L, Kim, M and Yun, CO (2010). A hypoxia-and {alpha}-fetoprotein-dependent oncolytic adenovirus exhibits specific killing of hepatocellular carcinomas. Clin Cancer Res 16: 6071-6082.
40. Yu, DC, Chen, Y, Dilley, J, Li, Y, Embry, M, Zhang, H et al. (2001). Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res 61: 517-525. (Pubitemid 32128610)